Please check your internet connection and try again.
# Lennox-Gastaut Syndrome (LGS)
## Overview
LGS is a severe form of childhood-onset epilepsy characterized by multiple seizure types (tonic, atonic, absence), cognitive impairment, and a characteristic slow spike-and-wave pattern on EEG. Management is typically polypharmacy-based, as monotherapy is rarely sufficient.
## Primary Indications
Adjunctive therapy for seizures associated with LGS. Common agents include Clobazam, Rufinamide, Topiramate, Valproic Acid, and Cannabidiol.
## Adult Dosing
* **Clobazam:** Start 5–10 mg/day, titrated to 20 mg/day (usually given in 2 divided doses).
* **Rufinamide:** Start 400–800 mg/day, titrated weekly. Maintenance: 1,600–3,200 mg/day in two divided doses.
* **Cannabidiol:** 10 mg/kg/day, titrated to 20 mg/kg/day over two weeks.
* **Topiramate:** 200–400 mg/day in two divided doses.
## Pediatric Dosing
* **Clobazam (≥2 years):** Weight <30 kg: Start 5 mg/day, target 10–20 mg/day. Weight ≥30 kg: Start 10 mg/day, target 20–40 mg/day.
* **Rufinamide (≥1 year):** Initial 10 mg/kg/day in two doses; increase by 10 mg/kg every other day. Max: 45 mg/kg/day (or 3,200 mg/day).
* **Cannabidiol (≥1 year):** Start 2.5 mg/kg BID (5 mg/kg/day); increase to 5 mg/kg BID (10 mg/kg/day) after one week. Target: 10 mg/kg BID.
* **Topiramate (≥2 years):** Titrate slowly to 5–9 mg/kg/day in two divided doses.
* **Valproic Acid:** 15–60 mg/kg/day in 2–3 divided doses.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting doses and titration rates for Valproic Acid, Clobazam, and Cannabidiol.
* **Renal Impairment:** Requires dose reductions for Topiramate and potentially Rufinamide.
* **Protocol:** Always consult local institutional protocols for specific titration schedules as rapid escalation can increase risk of adverse CNS effects.
## Contraindications
* **Valproic Acid:** Hepatic disease, urea cycle disorders, pregnancy (teratogenic).
* **Rufinamide:** Familial Short QT Syndrome.
* **Clobazam:** History of hypersensitivity (Stevens-Johnson syndrome risk).
## Adverse Effects
* **General:** Somnolence, fatigue, dizziness, and cognitive slowing (especially Topiramate).
* **Specific:**
* **Rufinamide:** QT shortening.
* **Cannabidiol:** Elevated transaminases, diarrhea, anorexia.
* **Valproic Acid:** Hepatotoxicity, hyperammonemia, thrombocytopenia.
* **Clobazam:** Dependence, respiratory depression with opioids.
## Key Drug Interactions
* **Valproic Acid:** Inhibits metabolism of many AEDs, potentially increasing levels of Topiramate or Rufinamide.
* **Clobazam:** CYP2C19 inhibitors can increase levels. Synergistic CNS depression with alcohol, benzodiazepines, and opioids.
* **Cannabidiol:** Increases levels of Clobazam's active metabolite (N-desmethylclobazam) and potentially phenytoin/valproate.
## Monitoring
* **Baseline/Routine:** Liver function tests (ALT/AST/Bilirubin) particularly for Cannabidiol and Valproic Acid.
* **Hematology:** CBC with differential (Valproic Acid).
* **Cardiac:** ECG (Rufinamide) to monitor for QT shortening/arrhythmias.
* **Clinical:** Seizure diary to assess efficacy and cognitive/behavioral status. Monitor for signs of suicidal ideation (class effect for AEDs).
## Clinical Pearls
* **Titration:** "Start low, go slow" is critical to minimize cognitive and somnolent adverse effects.
* **Clobazam/Cannabidiol:** The interaction between these two is significant; lower doses of Clobazam may be required when initiating CBD to avoid excessive sedation.
* **Valproate:** Usually a first-line backbone therapy, but avoid in patients with suspected mitochondrial disorders (Pol enzyme deficiency).
* **Refractory cases:** Consider Fenfluramine or Ketogenic diet if conventional agents fail.
***
**Disclaimer:** This information is intended for educational purposes for healthcare professionals. Clinical practice guidelines, regional availability, and prescribing information (e.g., FDA labels, EMA summaries) should be verified prior to medication administration, as dosing and safety protocols are subject to change.
